- Will CAR-NK Cancer Therapy Surpass High-Cost CAR-T Immunotherapy?
- What is the role of Platelet Dynamics in Cancer Progression?
- Biomarkers can detect rapid aging of organs and disease risks
- Avoiding “Off-Target” Effects: Researchers Enhance the Safety of Future mRNA Therapies
- Japan: Sales Halted for ‘Cannabis Gummies’ as Health Issues Mount
- Evaluation of the carcinogenicity of organic fluorine compounds raised by WHO subsidiary
14.6 billion doses of COVID-19 vaccines could be produced globally in 2021
14.6 billion doses of COVID-19 vaccines could be produced globally in 2021. In 2021, the total global production capacity of COVID-19 vaccine will reach 14.6 billion doses!
In 2021, the COVID-19 epidemic will be gradually controlled within a controllable range with the efforts of the people around the world; with the arrival of the post-epidemic era, the impact of the epidemic on people is profound and continuous, and the COVID-19 vaccine is still a top priority for humankind worldwide.
At present, the cumulative number of vaccinated people worldwide is close to 4 billion, and the vaccination in various countries has accelerated the progress.
In the development of a vaccine with a higher protection rate, the main focus of the world is on recombinant subunit proteins.
The epidemic has not slowed down, and vaccination is urgently needed
At present, Iran, India, Indonesia, the United Kingdom, and Russia are the five countries with the largest number of new confirmed cases, and Indonesia, Russia, Brazil, and India are the five countries with the largest number of new deaths.
According to Worldometer’s real-time statistics, as of July 26, Pacific time, there were a total of 195,279,354 confirmed cases of COVID-19 pneumonia worldwide, and a total of 4,181,853 deaths. There were 510,232 new confirmed cases and 7814 new deaths worldwide in a single day.
The global epidemic has repeated. With the mutation of the COVID-19 virus, the number of new diagnoses continues to increase every day, and the global epidemic has not yet shown a trend of slowing down; the COVID-19 vaccination is urgently needed.
Chart 1: Distribution of the cumulative number of confirmed cases of the global COVID-19 epidemic as of July 27, 2021
China has a large number of vaccinations, while Canada has a faster vaccination schedule
As of July 27, 2021, 3.93 billion doses have been vaccinated globally, and 1.08 billion people have been completely vaccinated. The prevention and control situation is improving.
Among them, China has the largest number of fully vaccinated people, reaching 223 million people, but the vaccination schedule is only 15.98%; Canada has the fastest vaccination schedule, reaching 56.33%, but the number of vaccinated people is only 21 million.
The global COVID-19 vaccine production capacity will reach 14.6 billion doses in 2021
According to statistics from the “Lancet” magazine, the total production capacity of the global COVID-19 vaccine in 2021 will reach 14.60 billion doses.
Among them, the largest production capacity is Pfizer-BioNTech, with a production capacity of 3 billion doses, accounting for 20.55% of the total production capacity; followed by AstraZeneca, accounting for 14.38%.
It is worth noting that the production capacity of COVID-19vaccines produced by several Chinese companies has reached more than 500 million doses.
Among them, Kexing Biological has the largest production capacity, accounting for 11.99% of the total production capacity.
Recombinant subunit protein is currently the mainstream of research and development
From the perspective of the distribution of vaccine technology platforms that have entered the research and development stage, new vaccine platforms such as protein subunits, viral vectors, and RNA have attracted much attention.
According to statistics from WHO, 31% of the 101 vaccine candidates currently entering clinical trials in the world use subunit protein as a technical route for vaccine design, and the remaining four vaccine technologies are non-replicatable viral vectors, DNA, inactivated and RNA. The routes account for 10-16% respectively. These 5 technical routes are relatively mature and can be smoothly applied and mass-produced.
The scale of the COVID-19 vaccine market will further expand
According to Morgan Stanley’s calculation and analysis, the COVID-19 vaccine may become a vaccine that people will get every year. To a certain extent, the COVID-19 vaccine may become one of the daily vaccines in the future.
According to Coherent Market Insights (CMI) forecasts, the COVID-19 vaccine market will reach $14.5 billion in 2021, and maintain a compound annual growth rate of 30.90% for rapid expansion. After preliminary calculations, the global COVID-19 vaccine market will reach 55.7 billion U.S. dollars in 2026.
(source:internet, reference only)
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.